Clinical Trials: Clinical Trials in UK

UK Clinical Trial Transparency Requirements

Posted on digi By digi

Transparency requirements may vary depending on the trial type:

Pediatric Trials: Plain-language summaries must be child-friendly and accessible to parents.
Rare Disease Trials: Data sharing is critical to enable global collaboration due to limited patient numbers.
Oncology Trials: High public interest requires timely and transparent dissemination of results.
Decentralized Trials: Additional transparency is needed for digital endpoints and eConsent processes.

Click to read the full article.

Clinical Trials in UK, Country-Specific Clinical Trials

Clinical Trial Insurance Requirements in the UK

Posted on digi By digi

Insurance in UK clinical trials is a non-negotiable regulatory requirement. Sponsors, investigators, and NHS Trusts must demonstrate adequate coverage to protect participants and ensure compliance. By following a step-by-step approach—securing coverage early, maintaining valid certificates, and preparing for REC/MHRA scrutiny—sponsors can avoid regulatory delays and ensure trials proceed smoothly while safeguarding patient welfare.
Click to read the full article.

Clinical Trials in UK, Country-Specific Clinical Trials

Academic Clinical Trials in the United Kingdom

Posted on digi By digi

Academic clinical trials in the UK are central to advancing healthcare, generating evidence for NHS practice, and addressing unmet patient needs. By following a step-by-step process—securing funding, identifying sponsors, obtaining approvals, ensuring insurance, and preparing for MHRA inspections—academic investigators can run compliant, impactful trials. With NIHR and NHS infrastructure support, UK academia continues to play a leading role in global clinical research.
Click to read the full article.

Clinical Trials in UK, Country-Specific Clinical Trials

Role of NIHR in UK Clinical Research

Posted on digi By digi

The NIHR is central to the UK’s clinical research ecosystem, enabling trials through funding, infrastructure, and workforce support. By engaging NIHR early and leveraging its networks, academic and industry sponsors can ensure efficient, transparent, and compliant trial delivery. NIHR’s integration with NHS priorities ensures research not only advances science but also directly benefits patients across the UK.
Click to read the full article.

Clinical Trials in UK, Country-Specific Clinical Trials

UK Clinical Trial Application Timelines vs EU

Posted on digi By digi

UK and EU trial application timelines differ post-Brexit but remain broadly harmonised with ICH standards. The UK offers a ~60-day approval window via MHRA/HRA, while EU CTR processes can extend beyond 100 days for multi-country trials. Sponsors should prepare robust dossiers, leverage fast-track options, and seek regulatory advice early to minimise delays and align global development plans.
Click to read the full article.

Clinical Trials in UK, Country-Specific Clinical Trials

Patient Recruitment Challenges in UK Clinical Studies

Posted on digi By digi

Patient recruitment challenges in UK clinical studies arise from systemic, logistical, and socio-cultural barriers. While NIHR and NHS provide strong infrastructure, sponsors must adopt simplified protocols, digital solutions, and inclusive engagement strategies to achieve recruitment goals. Early regulatory advice and proactive collaboration with NIHR and RECs are key to overcoming recruitment hurdles and delivering trials on time.
Click to read the full article.

Clinical Trials in UK, Country-Specific Clinical Trials

Risk-Based Monitoring in the UK Clinical Trial Context

Posted on digi By digi

Risk-based monitoring in the UK reflects a shift towards proportionate, patient-centred trial oversight. By following a step-by-step approach—starting with structured risk assessments, developing RBM plans, leveraging digital tools, and ensuring CRO oversight—sponsors can meet MHRA and HRA expectations while optimising resources. RBM is now an essential element of modern UK clinical trials, balancing efficiency with participant safety.
Click to read the full article.

Clinical Trials in UK, Country-Specific Clinical Trials